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Abstract
Background: Human-capital based lifetime productivity estimates are frequently used in cost-
of-illness (COI) analyses and, less commonly, in cost-effectiveness analyses (CEAs). Previous US 
estimates assumed that labor productivity and real earnings both grow by 1% per year.
Objectives: This study presents estimates of annual and lifetime productivity for 2016 using data 
from the American Community Survey, the American Time Use Survey, and the Current 
Population Survey, and with varying assumptions about real earnings growth.
Methods: The sum of market productivity (gross annual personal labor earnings adjusted for 
employer-paid benefits) and the imputed value of non-market time spent in household, caring, and 
volunteer services was estimated. The present value of lifetime productivity at various ages was 
calculated for synthetic cohorts using annual productivity estimates, life tables, discount rates, and 
assumptions about future earnings growth rates.
Results: Mean annual productivity was $57,324 for US adults in 2016, including $36,935 in 
market and $20,389 in non-market productivity. Lifetime productivity at birth, using a 3% 
discount rate, is roughly $1.5 million if earnings grow by 1% per year and $1.2 million if future 
earnings growth averages 0.5% per year.
Conclusions: Inclusion of avoidable productivity losses in societal-perspective CEAs of health 
interventions is recommended in new US cost-effectiveness guidelines. However, estimates vary 
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depending on whether analysts choose to estimate total productivity or just market productivity, 
and on assumptions made about growth in future productivity and earnings.
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Introduction
Estimates of productivity costs associated with morbidity, disability, and premature 
mortality, also referred to as indirect costs, are included in the majority of cost-of-illness 
(COI) analyses1–3. Productivity costs are important components of the preventable burden of 
chronic diseases and risk factors, such as smoking or obesity4,5. For example, estimated 
annual costs of cardiovascular disease in the US during 2012–2013 included $189.7 billion 
in direct medical costs and $126.4 billion in lost productivity resulting from premature 
mortality6. Including lost productivity from both premature mortality and disability, the 
economic burden of occupational injury and illness in the US in 2007 was estimated to be 
$250 billion, with $67 billion in direct medical costs and $183 billion in indirect costs7.
Productivity costs are included in some cost-effectiveness analyses (CEAs) from the societal 
perspective8. However, because of heterogeneous methods for estimating productivity 
losses9,10, findings of CEAs that are restricted to estimates of direct costs may be more 
comparable11. Until recently, CEA guidance documents did not recommend their inclusion. 
The First US Panel on Cost-effectiveness in Health and Medicine in 1996 recommended 
against inclusion of productivity costs in reference-case CEAs on the grounds that there 
could be double-counting of health effects between quality adjusted life-years (QALYs) and 
productivity costs, an argument that was subsequently challenged on the basis of evidence 
that that was not a serious issue12,13. In 2016, the Second US Panel on Cost-effectiveness in 
Health and Medicine (Second Panel) recommended that reference-case CEAs undertaken 
from the societal perspective use lifetime productivity estimates to value the benefit of 
avoided premature deaths14,15. Specifically, the panel recommended the use of human 
capital methods that include both market and non-market productivity as originally 
developed by US economists in the 1960s16–18. A few countries, notably the Netherlands, 
Canada, and Germany, have endorsed the friction cost method, which includes short-term 
market productivity losses19,20. The strengths and limitations of the human capital and 
friction cost methods have been extensively discussed in the literature, including two 
recently published review articles21,22. Potential modifications to the standard human capital 
approach, as discussed in both of those articles, are beyond the scope of the present study.
The most recent published lifetime market and non-market productivity estimates for the US 
are from a 2009 study by Grosse et al.23. That study, like previous US studies using the 
human capital approach, projected productivity in future years by assuming that current age–
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gender specific annual productivity or earnings would increase by 1% per year, in line with 
long-term growth in labor productivity, with the assumption that real earnings grow at the 
same rate as average labor productivity18,24–27. The change in the value of total employer 
compensation using the Employment Cost Index (ECI) for the total compensation of all 
civilian workers, adjusted for inflation, is a measure of real earnings growth. From 1981–
2004, the annual change in the constant-dollar ECI averaged 1%23. However, from 2004–
2016, the average annual growth in real employee compensation fell to 0.3–0.5% per year,1 
even though labor productivity grew at ~1% per year during that period.2
Methods
In accordance with previous US studies, we use the gross human capital approach to 
estimate annual and lifetime productivity by age and sex, including both market productivity 
(earnings) and non-market productivity (mostly household services).
Since 2006, the US Census Bureau’s American Community Survey (ACS) has covered the 
US resident population (50 states plus the District of Columbia) of persons living in private 
households, institutionalized group quarters, and non-institutionalized group quarters.3 
Using the 2016 ACS, we calculated the annual wages and salaries and self-employment 
income for persons aged 16 years and over by age and gender. At each age, the economic 
value of market productivity is set to the sum of gross employee compensation and self-
employment income earned at that age in the population, divided by the size of the non-
institutionalized population in that age group. ACS reports self-employment income 
separately from wage and salary income for individuals who report both types of income; 
many of those individuals own small businesses and draw both a salary and profit from the 
business, with the business profit reported as self-employment income.
Gross employee compensation is equal to wage and salary income multiplied by one plus 
average employer-paid benefits provided to all employees as a percentage of wages and 
salaries calculated using data from the Bureau of Economic Analysis (BEA). The BEA 
provides estimates of the total benefit cost (medical insurance, retirement benefits, and 
legally required benefits, such as Federal Insurance Contributions Act tax and 
unemployment) paid by civilian employers and the total wages and salaries paid to civilian 
employees in separate tables.4 The ratio of total benefits (annual value for 2016 in row 1 in 
BEA, Table 7.8) to total wages and salaries (average of 2016 quarterly values in row 1 of 
BEA, Table 2.2.B) was 23.4%. We multiplied mean money earnings from the ACS by a ratio 
of 1.234 to adjust for total employer compensation.
1.Current dollar ECI is available at https://www.bls.gov/data/ under Pay and Benefits. Real growth adjusted using the Consumer Price 
Index for Urban Consumers was 0.3% per year, and adjusting using the gross domestic product deflator was 0.5% per year28.
2.Calculated from data available in the Total Economy Database™ https://www.conference-board.org/data/economydatabase/
index.cfm?id=27762
3.Private households include houses, apartments, mobile homes, and rented rooms. Institutionalized group quarters include 
correctional facilities, nursing homes, and mental hospitals. Non-institutionalized group quarters include college dormitories, military 
barracks, group homes, missions, and shelters.
4.These data are reported by the BEA in their interactives tables: Table 2.2B. Wages and Salaries by Industry and Table 7.8. 
Supplements to Wages and Salaries by Type. The data are accessible beginning at https://www.bea.gov/iTable/index_nipa.cfm 
(October 23, 2017).
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At each age, the economic value of non-market productivity is the sum of the product of 
non-market work hours by age and the average hourly wage rate paid to personal and service 
occupation workers by age. American Time Use Survey (ATUS) 2016 data were used to 
estimate weekly hours of non-market work performed by the non-institutionalized 
population. Non-market work was set to the time spent in the following categories: 
performing household activities, caring and helping people, consumer purchases, volunteer 
activities, secondary childcare,5 and, beginning in 2011, other secondary eldercare.6 Caring 
and helping people was captured as time spent in primary activities other than household 
services in which someone monitored children under the age of 12 years as a secondary 
activity. Also included in non-market work is the time spent traveling for non-market work 
activities.7 Since time use data are not available in the ATUS for persons under age 15 or for 
those living in institutions, non-market productivity for those persons was set to zero.8
To value the average weekly hours of non-market work, we estimated the average hourly 
earnings of “personal care and service occupation workers” by gender and age as found in 
the Current Population Survey (CPS). The average hourly wages in 2016 were $11.66 for 
males and $11.00 for females. To the hourly service wage, we added private industry 
employers’ average hourly benefit costs as a percentage of their part-time service occupation 
workers’ total hourly earnings, as reported in the BLS Employer Cost of Employee 
Compensation survey.9 Employer costs for insurance, retirement, and savings, and legally 
required benefits as a percentage of total money hourly service occupation earnings averaged 
17.87% of hourly earnings in 2016.
The present value of remaining individual lifetime productivity at age X (e.g. 0 for birth) is 
estimated by summing expected annual productivity in future years weighted by population 
lifetable survival probabilities and applying a discount rate. Mean labor productivity at each 
future age is projected as the mean productivity, at that age in 2016, exponentiated using the 
assumed annual growth rate of real earnings (inclusive of benefits) applied to the difference 
in ages. Mean productivity at each age is multiplied by the probability of survival to that 
specific age. The present value of lifetime productivity at age X is calculated by applying an 
annual discount rate to the difference in years between future ages and age X.
Reflecting the observed slowdown in growth in real earnings during 2004–2016, we provide 
estimates under two assumptions of future annual real earnings growth: 0.5% and 1%.
Risk-of-survival productivity values were discounted to present values using two primary 
estimates of the real or inflation-free discount rates 3% and 7%. Unofficial US guidance 
5.Secondary childcare is defined in the ATUS as the time one has a child under 13 years “in his or her care” while doing something 
else as a primary activity.
6.Eldercare is defined in the ATUS as the time providing persons aged 65 or older with help needed due to a condition related to 
aging, such as assisting with grooming, preparing meals, and providing transportation.
7.Examples can be found in the ATUS Activity Lexicon: https://www.bls.gov/tus/lexiconwex2016.pdf (October 23, 2017). Time-based 
activities are not allowed to overlap. For example, if the “main” activity of a person is cooking, but the “cooking” is performed as part 
of eldercare, eldercare during that time is set to zero.
8.If non-market work data were available for institutionalized persons, we would expect those hours to be low compared to those in 
the non-institutional population.
9.The information can be found at https://www.bls.gov/data under Pay and Benefits. Since we value non-market services by-the-hour, 
the benefit rate should also be measured by-the-hour. This method differs from accounting for market benefits as a percentage of total 
personal earnings using the BEA estimates, which are based on gross annual payroll costs.
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recommends use of a 3% real discount rate for reference case CEAs14. The US Office of 
Management and Budget calls for both 3% and 7% discount rates in regulatory impact 
analyses29. Results for real discount rates from 0–10%, including single-age estimates from 
0–99 years, are posted as Online Supplementary Tables.
Results
Overview of annual and lifetime productivity estimates
The 2016 US resident population market, non-market, and total productivity annual mean 
values, by gender and age, are shown in Table 1. Male and female market productivity 
values diverge starting at childbearing years, due to both greater absence from the labor 
force while bearing and raising children and slower earnings growth with increasing age for 
females (Figure 1). Although average annual earnings draw closer in absolute dollar values 
at older ages, in relative terms there is no convergence. Non-market work productivity rises 
to a peak during child-raising years, and subsequently diminishes as children leave home 
(Figure 2). There is a bump in non-market productivity during retirement years, followed by 
a decline with advancing age. Females consistently outperform males in non-market 
productivity, which more than offsets their lower earnings until age 31. After age 31, higher 
male earnings more than offset lower non-market productivity.
In Table 2 and Figures 3 and 4, we show estimates of the lifetime present value of individual 
productivity at birth and selected ages from 16–90 years, using a 3% discount rate and either 
1% or 0.5% future productivity growth. Table 2 also reports results using a 7% discount rate.
Variation in future productivity growth, age, gender, and discount rate
Assuming 1% annual growth in employee compensation and a 3% discount rate, the present 
value of lifetime total productivity at birth, including market and non-market productivity, is 
~ $1.5 million. Assuming 0.5% annual growth in future real gross earnings and a 3% 
discount rate, the present value of productivity at birth is ~ $1.2 million. Present value 
estimates calculated using a 7% discount rate are lower, roughly $0.3 million at birth, 
regardless of the rate of future earnings growth.
The differential in present value of total productivity diminishes with age. At age 30, the 
present values using a 3% discount rate with 1% and 0.5% future earnings growth are $2.2 
million and $2.0 million, respectively, and, at age 50, both estimates are rounded to $1.2 
million. Using a 7% discount rate, the present value of total productivity is $1.2 million at 
age 30 and ~ $850,000 at age 50 for both 1% and 0.5% earnings growth rates.
Using a 3% discount rate, the present value of lifetime market productivity at birth in 2016 
was roughly $0.9 million assuming 1% future earnings growth, and $0.8 million assuming 
0.5% growth in future years. At age 30, the present values of earnings in 2016 are $1.4 
million and $1.3 million. Present value estimates calculated using a 7% discount rate are 
much lower, roughly $0.2 million at birth and $0.8 million at age 30.
Gender-specific lifetime productivity estimates are higher for males than females, especially 
when restricted to market productivity. At birth, the present values of market productivity, 
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assuming 1% future earnings growth and a 3% discount rate, are $1.1 million for males and 
$0.7 million for females. The corresponding estimates for total productivity in 2016 are $1.6 
million and $1.4 million, which reflect the larger expected value of non-market productivity 
for females.
Discussion
Relevancy of estimates
This study presents methodologically consistent estimates of market and non-market labor 
productivity by age and gender for the US resident population during 2016 on the basis of 
public use microdata from the ATUS, the CPS, and the ACS. Such estimates are essential to 
inform CEAs that follow the guidance of the Second Panel14. Unlike previously published 
estimates23,25,27, market productivity estimates incorporated self-employment income as 
well as earnings of employed workers. The ACS has a much larger sample size than the 
ATUS, allowing for the direct calculation of estimates of annual market productivity. Other 
methodological improvements include more comprehensive estimates of non-market time. 
Non-market productivity time averaged 4.5 hours per day in the present study, which 
compares with a mean of 3.1 hours per day in the study by Grosse et al.23. The increase was 
due primarily to the inclusion of time spent in secondary childcare, such as watching 
children while primarily engaged in leisure activities, such as watching television 
(Supplementary Appendix). We believe that this inclusion is justified because, if the 
caregiver were sick or disabled, another adult would need to take his or her place.
Estimates of lifetime market productivity alone may be relevant for economic evaluations of 
policies or interventions that avoid exposures that affect market productivity. For example, 
environmental health researchers have used estimates of the association of childhood 
exposures to contaminants, such as elemental lead, with cognitive ability and the association 
of cognitive ability with earnings to calculate the preventable economic burden of 
productivity losses due to childhood exposures to environmental contaminants, such as 
elemental lead environmental exposures30–32.
Accuracy of estimates
Accurate estimates of the indirect or productivity cost of disease or injury should be based 
on up-to-date estimates of the expected economic productivity of individuals in the general 
population. The slow growth in inflation-adjusted earnings in the US during the 2006–2016 
period implies that use of productivity estimates that assumed 1% annual growth in the real 
value of labor time overstated market and non-market productivity losses during that period. 
For example, according to Grosse et al.23, average annual gross earnings for women aged 
35–39 and 40–44 years were $33,464 and $35,870, respectively, in 2007 dollars. Projected 
forward, assuming 1% annual growth in earnings, the average earnings for women aged 35–
44 years in 2016 would have been $37,915 in 2007 dollars, or $43,399 in 2016 US dollars 
using the gross domestic product price deflator. The observed average market productivity 
for women aged 35–44 years in 2016 was $42,899 (Table 1), which is 1.3% lower than 
projected.
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Conversely, the more complete coverage of non-market productive activities in the present 
study is associated with larger age-specific estimates of annual non-market productivity than 
in Grosse et al.23. That is especially the case for women of childbearing age. For example, 
for women aged 35–44 years, average household productivity of $21,319 in 2007, 
corresponds to an inflation-adjusted estimate of $26,688 in 2016, assuming 1% annual 
productivity growth. In comparison, average non-market productivity for women in that age 
group in 2016 in the present study was $34,840, which is 31% higher.
Significance of estimates
The net effect on total annual productivity of these offsetting differences in market and non-
market productivity varied by demographic group. Total productivity for women aged 35–44 
years in 2016 ($77,679) was 11% higher than the inflation- and productivity growth-adjusted 
estimate from 2007. For men, on the other hand, total productivity in 2016 in real terms was 
close to projections from 2007 values, because increased estimates of non-market 
productivity almost exactly offset lower estimates of real earnings. For example, men aged 
45–54 years had 2.1% lower market productivity and 40.1% higher non-market productivity 
relative to 2007 estimates adjusted for inflation and earnings growth, with 2016 total 
productivity higher by just 4.1%.
Lifetime total productivity estimates in 2016, calculated assuming 1% future annual earnings 
growth and a 3% discount rate, are similar to the estimates from 2007 data. In 2007, lifetime 
productivity at birth was estimated to be roughly $1,180,796, which adjusted for inflation 
and 1% annual earnings growth is $1,478,207. This value is virtually the same as the 
calculated value of $1,468,669 in 2016, reflecting an 18.5% increase in non-market 
productivity estimates, almost exactly offsetting a 9.1% decrease in estimated lifetime 
market productivity. The 9.1% decrease in lifetime market productivity for 2016 relative to 
the predicted value based on the 2007 estimate is due to the assumption of 1% annual 
productivity growth between 2007 and 2016. The 2007 lifetime market productivity at birth 
estimate, $820,892, adjusted for inflation to 2016 dollars, is $939,624. That is slightly larger 
than the 2016 estimate, $934,583, compared with a predicted value of $1,027,653 assuming 
real growth of 1% per year during that 9-year period.
The magnitude of future growth in real earnings, which is uncertain, affects human capital 
estimates of lifetime productivity. That is also true for non-market productivity, which is 
indexed to the real earnings of service workers. Lifetime productivity at birth in 2016 was 
23% higher in estimates that assumed 1% annual earnings growth relative to those that 
incorporated 0.5% annual earnings growth (Table 2). The lack of growth in observed real 
per-person earnings between 2007 and 2016 implies that the assumption of 1% annual 
earnings growth might be optimistic. The gap between growth rates in real earnings and 
growth in labor productivity in the US since 2004 has multiple explanations. A widely 
reported long-term decline in the labor share in national income in high-income countries 
since the early 1980s has been attributed by experts to structural factors such as 
globalization and increased market concentration in many high-income countries33–35. 
Either temporary or structural distortions in labor markets can call into question the 
neoclassical basis for the standard human capital approach. It could be useful for researchers 
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to document trends in estimates of growth in real earnings and labor productivity in other 
high-income countries, as well as country-specific estimates of changes over time in market 
concentration. On the other hand, the US Congressional Budget Office (CBO) has posited 
that the recent decline in the US labor share will reverse itself36 and optimistically projects 
that growth in both labor productivity and real earnings will increase in coming years; in 
2017 CBO projected 1.1% annual growth in real earnings per worker over the coming 
decade, and in 2018 CBO raised the projected growth in real earnings to 1.5% per year37,38.
Debate over inclusion of productivity costs in economic evaluations
Although the inclusion of productivity costs in health-related economic evaluations has been 
debated for years, fewer than 10% of cost-effectiveness analyses include productivity 
costs21,39. However, with the new recommendation to include productivity costs in CEAs 
from the societal perspective, it is important to consider the implications of excluding 
productivity costs from pharmacoeconomic evaluations39. In a 2011 systematic review of 
cost analyses of treatments for depressive disorders, researchers found that productivity 
costs accounted for 60% on average of total costs40. Including productivity estimates could 
lead to certain interventions that would be considered too costly to implement, based on 
direct costs alone, being reclassified as cost-effective41.
Conclusion
The economic impact of premature mortality and disability is often incorporated in analyses 
of economic burden of disease and is increasingly included in CEAs from the societal 
perspective. Such analyses require updated estimates of the present value of expected 
productivity over the remaining lifetime. Adjustment of historic estimates for changes in 
price levels is inadequate; updated estimates that reflect changed labor force attachment and 
age-earnings profiles as well as current estimates of non-market productivity and uncertainty 
in future earnings growth may be more informative. Although it has long been standard 
practice to assume that labor productivity and earnings will grow indefinitely at a constant 
rate of 1% per year, because of uncertainty in earnings growth a range of estimates may be 
more informative. This issue is particularly timely, since the Second Panel in 2016 
recommended that reference-case analyses from the societal perspective include expected 
decrements to productivity that result from disease, disability, or death as preventable 
costs14.
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Figure 1. 
Resident population market productivity annual mean values by gender and age, 2016 US 
dollars.
Legend.  Both sexes  Males  Females
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Figure 2. 
Resident population non-market productivity annual mean values by gender and age, 2016 
US dollars.
Legend.  Both sexes  Males  Females
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Figure 3. 
Lifetime present value of individual productivity at birth and selected ages from 16–90 years 
using a 3% discount rate and 1% future productivity growth, 2016 US dollars.
Legend.  Both sexes  Males  Females
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Figure 4. 
Lifetime present value of individual productivity at birth and selected ages from 16–90 years 
using a 3% discount rate and 0.5% future productivity growth, 2016 US dollars.
Legend.  Both sexes  Males  Females
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